JACC. Heart failure最新文献

{"title":"Functional Status and Quality of Life in Light-Chain Amyloidosis","authors":"Olivier F. Clerc MD, MPH ,&nbsp;Shilpa Vijayakumar MD, MPH ,&nbsp;Sarah A.M. Cuddy MD ,&nbsp;Giada Bianchi MD ,&nbsp;Jocelyn Canseco Neri MS ,&nbsp;Alexandra Taylor BS ,&nbsp;Dominik C. Benz MD ,&nbsp;Yesh Datar BA ,&nbsp;Marie Foley Kijewski PhD ,&nbsp;Andrew J. Yee MD ,&nbsp;Frederick L. Ruberg MD ,&nbsp;Ronglih Liao PhD ,&nbsp;Rodney H. Falk MD ,&nbsp;Vaishali Sanchorawala MD ,&nbsp;Sharmila Dorbala MD, MPH","doi":"10.1016/j.jchf.2024.07.007","DOIUrl":"10.1016/j.jchf.2024.07.007","url":null,"abstract":"<div><h3>Background</h3><div>In light-chain (AL) amyloidosis, whether functional status and heart failure–related quality of life (HF-QOL) correlate with cardiomyopathy severity, improve with therapy, and are associated with major adverse cardiac events (MACE) beyond validated scores is not well-known.</div></div><div><h3>Objectives</h3><div>The authors aimed to: 1) correlate functional status and HF-QOL with cardiomyopathy severity; 2) analyze their longitudinal changes; and 3) assess their independent associations with MACE.</div></div><div><h3>Methods</h3><div>This study included 106 participants with AL amyloidosis, with 81% having AL cardiomyopathy. Functional status was evaluated using the NYHA functional class, the Karnofsky scale, and the 6-minute walk distance (6MWD), and HF-QOL using the MLWHFQ (Minnesota Living with Heart Failure Questionnaire). Cardiomyopathy severity was assessed by cardiac ¹⁸F-florbetapir positron emission tomography/computed tomography, cardiac magnetic resonance, echocardiography, and serum cardiac biomarkers. MACE were defined as all-cause death, heart failure hospitalization, or cardiac transplantation.</div></div><div><h3>Results</h3><div>NYHA functional class, Karnofsky scale, 6MWD, and MLWHFQ were impaired substantially in participants with recently diagnosed AL cardiomyopathy (<em>P &lt;</em> 0.001), and correlated with all markers of cardiomyopathy severity (<em>P ≤</em> 0.010). NYHA functional class, 6MWD, and MLWHFQ improved at 12 months in participants with cardiomyopathy (<em>P ≤</em> 0.013). All measures of functional status and HF-QOL were associated with MACE (<em>P ≤</em> 0.017), independent of Mayo stage for 6MWD and MLWHFQ (<em>P ≤</em> 0.006).</div></div><div><h3>Conclusions</h3><div>Functional status and HF-QOL were associated with AL cardiomyopathy severity, improved on therapy within 12 months, and were associated with MACE, independently of Mayo stage for 6MWD and MLWHFQ. They may be validated further in addition to prognostic scores and as surrogate outcomes for future studies.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 12","pages":"Pages 1994-2006"},"PeriodicalIF":10.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating The Complex Path From Monogenic to Polygenic Clinical Genetic Testing in Hypertrophic Cardiomyopathy","authors":"Roddy Walsh PhD","doi":"10.1016/j.jchf.2024.10.004","DOIUrl":"10.1016/j.jchf.2024.10.004","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 12","pages":"Pages 2053-2056"},"PeriodicalIF":10.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full Issue PDF","authors":"","doi":"10.1016/S2213-1779(24)00738-8","DOIUrl":"10.1016/S2213-1779(24)00738-8","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 12","pages":"Pages i-clxxii"},"PeriodicalIF":10.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Quality of Life Response Observed in the Baroreflex Activation Therapy for Heart Failure Trial","authors":"Samuel F. Sears PhD ,&nbsp;Elizabeth Jordan BA ,&nbsp;JoAnn Lindenfeld MD ,&nbsp;William T. Abraham MD ,&nbsp;Fred A. Weaver MD ,&nbsp;Faiez Zannad MD ,&nbsp;Tyson Rogers MS ,&nbsp;Fares Yared MD ,&nbsp;Seth J. Wilks PhD ,&nbsp;Michael R. Zile MD","doi":"10.1016/j.jchf.2024.07.013","DOIUrl":"10.1016/j.jchf.2024.07.013","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 12","pages":"Pages 2110-2112"},"PeriodicalIF":10.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Drives Transplant Outcomes Following Donation After Circulatory Death","authors":"Maryjane Farr MD, MSc ,&nbsp;Sean Pinney MD","doi":"10.1016/j.jchf.2024.07.008","DOIUrl":"10.1016/j.jchf.2024.07.008","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 12","pages":"Pages 2084-2086"},"PeriodicalIF":10.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mineralocorticoid Antagonism in Heart Failure","authors":"Joycie Chang BA ,&nbsp;Andrew P. Ambrosy MD ,&nbsp;Orly Vardeny PharmD, MS ,&nbsp;Harriette G.C. Van Spall MD, MPH ,&nbsp;Robert J. Mentz MD ,&nbsp;Andrew J. Sauer MD","doi":"10.1016/j.jchf.2024.08.007","DOIUrl":"10.1016/j.jchf.2024.08.007","url":null,"abstract":"<div><div>The pathophysiology of heart failure (HF) is related to the overactivation of the mineralocorticoid receptor, leading to fluid retention and adverse myocardial remodeling. Although mineralocorticoid receptor antagonists (MRAs) are recommended for the treatment of heart failure with reduced ejection fraction (HFrEF), they remain underused due to adverse effects such as hyperkalemia; and their efficacy is controversial in heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF). Recent trials in people with diabetes and kidney disease have supported the use of nonsteroidal MRAs in reducing HF-related morbidity and mortality and have fewer side effects than their steroidal counterparts. The efficacy and safety of nonsteroidal MRAs have not been tested in HF and are currently being evaluated in additional clinical trials. This review comprehensively examines the current data regarding MRAs for HF and the future direction of nonsteroidal MRA research while exploring the causes of MRA underutilization.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 12","pages":"Pages 1979-1993"},"PeriodicalIF":10.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Inpatient Percutaneous Coronary Intervention Volume on 30-Day Readmissions After Acute Myocardial Infarction-Cardiogenic Shock","authors":"Kannu Bansal MD ,&nbsp;Mohak Gupta MD ,&nbsp;Mohil Garg MD ,&nbsp;Neel Patel MD ,&nbsp;Alexander G. Truesdell MD ,&nbsp;Mir Babar Basir DO ,&nbsp;Syed Tanveer Rab MD ,&nbsp;Tariq Ahmad MD, MPH ,&nbsp;Navin K. Kapur MD ,&nbsp;Nihar Desai MD, MPH ,&nbsp;Saraschandra Vallabhajosyula MD, MSc","doi":"10.1016/j.jchf.2024.07.014","DOIUrl":"10.1016/j.jchf.2024.07.014","url":null,"abstract":"<div><h3>Background</h3><div>There are limited data on volume-outcome relationships in acute myocardial infarction (AMI) with cardiogenic shock (CS).</div></div><div><h3>Objectives</h3><div>In this study, the authors sought to evaluate the association between hospital percutaneous coronary intervention (PCI) volume and readmission after AMI-CS.</div></div><div><h3>Methods</h3><div>Adult AMI-CS patients were identified from the Nationwide Readmissions Database for 2016-2019 and were categorized into hospital quartiles (Q1 lowest volume to Q4 highest) based on annual inpatient PCI volume. Outcomes of interest included 30-day all-cause, cardiac, noncardiac, and heart-failure (HF) readmissions.</div></div><div><h3>Results</h3><div>There were 49,558 AMI-CS admissions at 3,954 PCI-performing hospitals. Median annual PCI volume was 174 (Q1-Q3: 70-316). Patients treated at Q1 hospitals were on average older, female, and with higher comorbidity burden. Patients at Q4 hospitals had higher rates of noncardiac organ dysfunction, complications, and use of cardiac support therapies. Overall, 30-day readmission rate was 18.5% (n = 9,179), of which cardiac, noncardiac, and HF readmissions constituted 56.2%, 43.8%, and 25.8%, respectively. From Q1 to Q4, there were no differences in 30-day all-cause (17.6%, 18.4%, 18.2%, 18.7%; <em>P =</em> 0.55), cardiac (10.9%, 11.0%, 10.6%, 10.2%; <em>P =</em> 0.29), and HF (5.0%, 4.8%, 4.8%, 4.8%; <em>P =</em> 0.99) readmissions. Noncardiac readmissions were noted more commonly in higher quartiles (6.7%, 7.4%, 7.7%, 8.5%; <em>P =</em> 0.001) but was not significant after multivariable adjustment. No relationship was noted between hospital PCI volume as a continuous variable and readmissions.</div></div><div><h3>Conclusions</h3><div>In AMI-CS, there was no association between hospital annual PCI volume and 30-day readmissions despite higher acuity in the higher volume PCI centers suggestive of better care pathways for CS at higher volume centers.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 12","pages":"Pages 2087-2097"},"PeriodicalIF":10.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patiromer and MRA Doses in Patients With Current or Past Hyperkalemia","authors":"João Pedro Ferreira MD, PhD","doi":"10.1016/j.jchf.2024.07.020","DOIUrl":"10.1016/j.jchf.2024.07.020","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 12","pages":"Pages 2038-2040"},"PeriodicalIF":10.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Undiagnosed Diabetes in Heart Failure With Preserved Ejection Fraction","authors":"John W. Ostrominski MD ,&nbsp;Mats C. Højbjerg Lassen MD ,&nbsp;Brian L. Claggett PhD ,&nbsp;Akshay S. Desai MD ,&nbsp;Marc A. Pfeffer MD, PhD ,&nbsp;Bertram Pitt MD ,&nbsp;Carolyn S.P. Lam MBBS, PhD ,&nbsp;John J.V. McMurray MD ,&nbsp;Scott D. Solomon MD ,&nbsp;Muthiah Vaduganathan MD, MPH","doi":"10.1016/j.jchf.2024.07.021","DOIUrl":"10.1016/j.jchf.2024.07.021","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 12","pages":"Pages 2116-2119"},"PeriodicalIF":10.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uric Acid and SGLT2 Inhibition With Empagliflozin in Heart Failure With Preserved Ejection Fraction","authors":"Wolfram Doehner MD, PhD ,&nbsp;Stefan D. Anker MD, PhD ,&nbsp;Javed Butler MD, MPH, MBA ,&nbsp;Faiez Zannad MD, PhD ,&nbsp;Gerasimos Filippatos MD ,&nbsp;Andrew J.S. Coats DM ,&nbsp;João Pedro Ferreira MD, PhD ,&nbsp;Ingrid Henrichmoeller MD ,&nbsp;Martina Brueckmann MD ,&nbsp;Elke Schueler Dipl Math ,&nbsp;Stuart J. Pocock PhD ,&nbsp;James L. Januzzi MD ,&nbsp;Milton Packer MD","doi":"10.1016/j.jchf.2024.08.020","DOIUrl":"10.1016/j.jchf.2024.08.020","url":null,"abstract":"<div><h3>Background</h3><div>Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve outcome in patients with heart failure (HF) and reduce serum uric acid (SUA). The relevance of this metabolic effect in patients with heart failure with preserved ejection fraction (HFpEF) is unclear.</div></div><div><h3>Objectives</h3><div>The authors investigated the effect of empagliflozin on SUA levels in relation to the therapeutic efficacy in patients with HFpEF.</div></div><div><h3>Methods</h3><div>This post hoc analysis of the EMPEROR-Preserved (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction; <span><span>NCT03057951</span><svg><path></path></svg></span>) trial assessed the clinical effect of SUA reduction in relation to the outcome endpoints of the trial (composite primary outcome of cardiovascular mortality or hospitalization for HF, its individual components, and all-cause mortality in patients with HFpEF).</div></div><div><h3>Results</h3><div>Hyperuricemia (SUA &gt;5.7 mg/dL for women, &gt;7.0 mg/dL for men) was prevalent in 49% of patients. Elevated SUA (highest tertile SUA 8.8 ± 1.4 g/dL) was associated with advanced HF severity and with higher risk of adverse outcome (primary endpoint HR: 1.23 [95% CI: 0.98-1.53]; <em>P =</em> 0.07; HF hospitalization HR: 1.42 [95% CI: 1.08-1.86]; <em>P =</em> 0.01). SUA was reduced early (after 4 weeks vs placebo −0.99 ± 0.03 mg/dL; <em>P &lt;</em> 0.0001) and throughout follow-up, with reduction in all prespecified subgroups. Empagliflozin reduced clinical events of hyperuricemia (acute gout, gouty arthritis, or initiation of antigout therapy) by 38% (HR: 0.62 [95% CI: 0.51-0.76]; <em>P &lt;</em> 0.0001). The treatment benefit on the primary endpoint was not influenced by baseline SUA (HR: 0.79 [95% CI: 0.69-0.90]; <em>P =</em> 0.0004). The change in SUA was an independent correlate of the treatment benefit on the primary endpoint (<em>P =</em> 0.07).</div></div><div><h3>Conclusions</h3><div>Hyperuricemia is a common complication in HFpEF and is related to advanced disease severity and adverse outcome. Empagliflozin induced a rapid and sustained reduction of SUA levels and of clinical events related to hyperuricemia.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"12 12","pages":"Pages 2057-2070"},"PeriodicalIF":10.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}